We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Major International Conferences to Hear About the Risks and Rewards of Synthetic Biology

Read time: Less than a minute

Representatives from Integrated DNA Technologies (IDT) will be describing efforts to prevent the misuse of synthetic genomics, and presenting recent developments in RNAi research, at Analytica, Munich, 1-4 April and the RNAi World Congress, Boston, MA, 30 April – 2 May.

At Analytica, Damon Terrill, Sr. VP International Legal and Regulatory Affairs, will present on the cooperative efforts of government and industry to counter the potential misuse of synthetic genomics for harmful purposes.

IDT is at the forefront of work by companies to develop improved gene sequence screening methods and protocols for reporting and responding to possible security and safety risks. IDT’s leadership in the U.S. prompted the European Industry Association on Synthetic Biology (IASB) to invite IDT to discuss with Analytica attendees from around the world the benefits of a truly international approach.

At the end of April, the emphasis shifts to exciting new areas in basic scientific research with Dr Mark Behlke, IDT’s Sr. Vice President of Molecular Genetics & Biophysics and Chief Scientific Officer, presenting on the “Use of Dicer-Substrate siRNAs in Animal Research” and “Evolution of miRNAs in the Marsupial Monodelphis domestica”.

New research carried out by Dr Behlke’s group reports on a number of interesting findings in RNAi research in several different model systems, including studies done in rats, mice and opossums.